Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Warning Letter Hits Akorn’s Subpar Root Cause Investigations

Jul 10 2019

• By Joanne S. Eglovitch

Warning Rubber Stamp

Related Content

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Jan 07 2019

The Quality Lowdown: EU/Japan MRA, Field Alerts, Akorn, New Pfizer Plant, And The Answer Is Continuous Manufacturing

Jul 30 2018

Aurobindo Faulted In US FDA Warning Letter For Poor Root Cause Investigations

Jul 03 2019

FDA Warning Letter To Teva Highlights Need For Accurate Root Cause Investigations

Mar 11 2019

Why Data Integrity Concerns Led Fresenius To Back Away From Akorn Deal

May 14 2018

Related Companies

Akorn, Inc.

Fresenius SE & Co. KGaA

Additional Topics

United States Manufacturing Quality Enforcement BioPharmaceutical

More from Manufacturing

More from Compliance

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window